Page last updated: 2024-11-03

rabeprazole and Adenoma

rabeprazole has been researched along with Adenoma in 5 studies

Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Adenoma: A benign epithelial tumor with a glandular organization.

Research Excerpts

ExcerptRelevanceReference
"Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs)."9.22Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016)
"In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66)."5.22Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy. ( Akahoshi, K; Akiho, H; Aso, A; Harada, N; Iboshi, Y; Ihara, E; Iwasa, T; Nakamura, K; Nakamura, N; Ochiai, T; Ogino, H; Takayanagi, R, 2016)
"Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs)."5.22Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016)
"Patients with early gastric cancers that are limited to gastric mucosa or submucosa usually have an advanced loss of mucosal glandular tissue (glandular atrophy) and are at high risk for subsequent (metachronous) development of new gastric cancer."2.87Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. ( Cho, SJ; Choi, IJ; Kim, CG; Kim, YI; Kook, MC; Lee, JY; Nam, BH; Park, B, 2018)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Choi, IJ1
Kook, MC1
Kim, YI1
Cho, SJ1
Lee, JY1
Kim, CG1
Park, B1
Nam, BH1
Hikichi, T1
Sato, M1
Watanabe, K1
Nakamura, J1
Takagi, T1
Suzuki, R1
Sugimoto, M1
Waragai, Y1
Kikuchi, H1
Konno, N1
Ohira, H1
Obara, K1
Nakamura, K1
Ihara, E1
Akiho, H1
Akahoshi, K1
Harada, N1
Ochiai, T1
Nakamura, N1
Ogino, H1
Iwasa, T1
Aso, A1
Iboshi, Y1
Takayanagi, R1
Kagawa, T1
Iwamuro, M1
Ishikawa, S1
Ishida, M1
Kuraoka, S1
Sasaki, K1
Sakakihara, I1
Izumikawa, K1
Yamamoto, K1
Takahashi, S1
Tanaka, S1
Matsuura, M1
Hasui, T1
Wato, M1
Inaba, T1
Sato, H1
Abe, K1
Oshima, N1
Kawashima, K1
Hamamoto, N1
Moritani, M1
Mak, R1
Ishihara, S1
Adachi, K1
Kawauchi, H1
Kinoshita, Y1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Metachronous Cancer in Patients Undergoing Endoscopic Mucosal Resection for Gastric Cancer[NCT02407119]Phase 3470 participants (Actual)Interventional2003-06-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

4 trials available for rabeprazole and Adenoma

ArticleYear
Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer.
    The New England journal of medicine, 2018, Mar-22, Volume: 378, Issue:12

    Topics: Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug

2018
Oral rabeprazole administration on a procedure day suppresses bleeding after endoscopic submucosal dissection for gastric neoplasms.
    Fukushima journal of medical science, 2014, Volume: 60, Issue:1

    Topics: Adenocarcinoma; Adenoma; Administration, Oral; Aged; Aged, 80 and over; Female; Gastrointestinal Hem

2014
Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
    Gut and liver, 2016, Nov-15, Volume: 10, Issue:6

    Topics: Adenoma; Aged; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopic Mucosal Resection;

2016
Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:6

    Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage;

2016

Other Studies

1 other study available for rabeprazole and Adenoma

ArticleYear
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
    Internal medicine (Tokyo, Japan), 2002, Volume: 41, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal

2002